Royal Bank of Canada Cuts Avantor (NYSE:AVTR) Price Target to $31.00

Avantor (NYSE:AVTR) had its price objective decreased by Royal Bank of Canada from $33.00 to $31.00 in a research note published on Monday,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock.

AVTR has been the subject of several other research reports. Raymond James decreased their price target on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Barclays decreased their price target on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Monday. Robert W. Baird decreased their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Wells Fargo & Company decreased their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Stifel Nicolaus decreased their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Monday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $26.15.

Avantor Stock Down 1.8 %

Shares of NYSE AVTR opened at $18.06 on Monday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The company has a market cap of $12.29 billion, a P/E ratio of 39.26, a PEG ratio of 3.87 and a beta of 1.28. Avantor has a 1 year low of $18.00 and a 1 year high of $28.00. The firm has a 50-day simple moving average of $21.63 and a two-hundred day simple moving average of $23.39.

Avantor (NYSE:AVTR) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the prior year, the company earned $0.22 earnings per share. Research analysts anticipate that Avantor will post 0.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVTR. MassMutual Private Wealth & Trust FSB lifted its position in Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after purchasing an additional 625 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Avantor by 106.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after acquiring an additional 830 shares during the period. UMB Bank n.a. acquired a new position in shares of Avantor in the third quarter worth about $49,000. Global Retirement Partners LLC raised its position in shares of Avantor by 76.7% in the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after acquiring an additional 1,067 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in shares of Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.